Genetic Technologies (ASX:GTG) announces the execution of a strategic joint sales & marketing agreement with US-based Wellworks for You. As part of the agreement, Wellworks will incorporate the geneType portfolio of tests into its wellness solutions for organizations and businesses across the US, providing direct access to more than two million personnel.
- Wellworks provides a personalised approach for corporate wellness for US employers and their employees
- The partnership will provide access to Wellworks’ 750 employer groups and includes more than 2,000,000 covered lives
- Wellworks will refer their clients, employer groups and their employees, to geneType for Risk Assessment Testing as part of their overall corporate wellness program.
Genetic Technologies’ CEO, Simon Morriss, said “We are incredibly excited about our partnership with Wellworks. Wellworks is leading the way in providing corporate wellness programs across their employer networks. Genetic Technologies and Wellworks believe inclusion of the geneType Risk Assessment portfolio will provide a major point of differentiation for both companies, this a major step forward for Genetic Technologies on our pathway to profitability”.
Wellworks CEO, Thomas Tegler, noted “Including the geneType Risk Assessment tests in our offering highlights our company’s commitment to well-being solutions that are not one-size-fits-all. Wellworks’ success has been built on custom-designed, data-supported programs. GeneType will be a strong addition to our portfolio and support our wellness strategy”.